Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,643)	$ (70,572)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on impairment of goodwill	0	60,934
Depreciation and amortization	2,109	2,075
Stock-based compensation	54	1,217
Change in fair value of royalties payable due to related parties	2,239	(7,208)
Deferred income tax provision	3,141	0
Changes in operating assets and liabilities:
Accounts receivable	67	(66)
Inventories	(8)	8
Prepaid expenses and other current assets	99	876
Operating lease right-of-use assets and lease liabilities	(3)	4
Current portion of royalties payable due to related parties	32	0
Accounts payable	(234)	(550)
Accrued expenses	(185)	(7,139)
Interest payable due to related parties	61	(198)
Net cash used in operating activities	(9,271)	(20,619)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(67)	(76)
Cash acquired as part of business combination	0	15
Net cash used in investing activities	(67)	(61)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs	2,612	0
Proceeds from notes payable due to related parties	1,500	0
Payment on notes payable	(256)	(107)
Proceeds from notes payable	249	0
Proceeds from exercise of warrants	1,185	1,326
Payment of costs related to the warrant repricing	0	(181)
Payment of convertible promissory notes and accrued interest	0	(250)
Proceeds from the private placement of securities	0	8,000
Net cash provided by financing activities	8,646	8,386
NET CHANGE IN CASH AND CASH EQUIVALENTS	(692)	(12,294)
CASH AND CASH EQUIVALENTS, beginning of year	3,565	15,859
CASH AND CASH EQUIVALENTS, end of year	2,873	3,565
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	31	204
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Property and equipment reclassified from inventories	19	0
Non-cash consideration for Catheter acquisition	0	72,544
Deemed dividend on warrant inducement offer	(5,158)	(800)
Conversion of Series A Convertible Preferred Stock into Common Stock [Member]
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Conversion of Series A Convertible Preferred Stock for common stock	0	1
Public Offering and At-the-market Sales Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	0	238
The 2024 Inducement Offer [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	3,356	0
Private Placement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs related to the private placement of securities	$ 0	$ (640)